{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"18.2","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.\n\ngemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle","id":"OG000","title":"Gemcitabine+Doxorubicin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the time of initial therapy until the time of death.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}